Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90
Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory
Breast and Ovarian Cancers at ASCO
Clinical Benefit Shown in 35% of HER2-Positive Metastatic BreastCancer Patients HAYWARD, Calif., June 04, 2007 /PRNewswire-FirstCall/ --
KosanBiosciences Incorporated presented data from a Phase 1 clinicaltrial showing that alvespimycin, its second-generation Hsp90inhibitor, demonstrated promising antitumor activity andtolerability in combination with trastuzumab (Herceptin(R)) inpatient...
Kosan Presents Phase 1 Data Showing Promising Antitumor Activity
and Safety Profile of Epothilone KOS-1584 at ASCO
HAYWARD, Calif., June 04, 2007 /PRNewswire-FirstCall/ --
KosanBiosciences Incorporated presented data from a Phase 1 clinicaltrial showing that KOS-1584/R1645, an epothilone underco-development with Roche, demonstrated promising antitumoractivity and tolerability in patients with solid tumors.KOS-1584/R1645 showed activity in 32% of patients (13 of 41evaluable) including activity in pati...
Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing
Promising Antitumor Activity in Multiple Myeloma at ASCO
Tanespimycin TIME Registration Program to Begin Third Quarter 2007 HAYWARD, Calif., June 04, 2007 /PRNewswire-FirstCall/ --
KosanBiosciences Incorporated presented data from a dose-escalatingPhase 1b clinical trial of its lead Hsp90 inhibitor, tanespimycin(KOS-953) in combination with bortezomib (Velcade(R)), showing ahigh degree of antitumor activity and tolerability in patients withmult...
Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity
of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO
HAYWARD, Calif., June 04, 2007 /PRNewswire-FirstCall/ --
KosanBiosciences Incorporated presented preliminary data from a Phase 2monotherapy trial showing that tanespimycin demonstrated antitumoractivity and tolerability in patients with metastatic melanoma,including one patient with a BRAF mutation (V600E) who had failedprior chemotherapy (within 6 weeks of initiation) and while ontanesp...
Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel
Anticancer Agents, at AACR
HAYWARD, Calif., April 18, 2007 /PRNewswire-FirstCall/ --
KosanBiosciences Incorporated today presented preclinical data on itsproprietary nuclear export inhibitors (NEI) showing induction ofpotent, fast-acting and long-lasting anticancer activity with ahigh degree of tolerability in multiple human tumor xenograftcancer models.
Kosan's NEIs are potent, specific inhibitors of CRM1,...
More>>